
ALFASIGMA ACQUIRES THE ENTIRE SHARE CAPITAL OF SOFAR, AN ITALIAN PHARMACEUTICAL COMPANY
The acquisition process, already announced last August, was completed on schedule and marks the beginning of the integration process of the two companies.
Alfasigma steadies its leadership in the gastrointestinal area and in the research on microbiota by aiming to expand its presence in the international market.